Published in Thorax on February 08, 2008
Human Laboratory Study Of Varenicline in Smokers | NCT00709696
Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. CMAJ (2011) 6.19
Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med (2015) 5.92
Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation (2010) 4.50
Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ (2012) 3.09
Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis. Circulation (2013) 2.73
Varenicline for tobacco dependence. N Engl J Med (2008) 2.70
Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. Lancet Respir Med (2015) 2.12
Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. J Neurogenet (2009) 2.07
Strategies to help a smoker who is struggling to quit. JAMA (2012) 1.68
Suicidal behavior and depression in smoking cessation treatments. PLoS One (2011) 1.65
The use of snus for quitting smoking compared with medicinal products. Nicotine Tob Res (2010) 1.43
Adverse events associated with nicotine replacement therapy (NRT) for smoking cessation. A systematic review and meta-analysis of one hundred and twenty studies involving 177,390 individuals. Tob Induc Dis (2010) 1.27
The alpha4beta2 nicotinic acetylcholine-receptor partial agonist varenicline inhibits both nicotine self-administration following repeated dosing and reinstatement of nicotine seeking in rats. Psychopharmacology (Berl) (2009) 1.24
Effectiveness of varenicline versus nicotine replacement therapy for smoking cessation with minimal professional support: evidence from an English population study. Psychopharmacology (Berl) (2013) 1.14
Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor. J Pharmacol Exp Ther (2011) 1.10
Efficacy of pharmacotherapies for short-term smoking abstinance: a systematic review and meta-analysis. Harm Reduct J (2009) 1.06
Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat (2008) 1.03
Varenicline for smoking cessation among methadone-maintained smokers: a randomized clinical trial. Drug Alcohol Depend (2013) 1.01
Mechanistic insights into nicotine withdrawal. Biochem Pharmacol (2011) 0.98
Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study. AIDS Patient Care STDS (2011) 0.98
Varenicline for Smoking Cessation in Schizophrenia: Safety and Effectiveness in a 12-Week, Open-Label Trial. J Dual Diagn (2012) 0.97
Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. Br J Clin Pharmacol (2014) 0.94
Prospective cohort study of the effectiveness of varenicline versus nicotine replacement therapy for smoking cessation in the "real world". BMC Public Health (2014) 0.93
Risk factor management to prevent first stroke. Neurol Clin (2008) 0.92
Pharmacogenetics of smoking cessation: role of nicotine target and metabolism genes. Hum Genet (2012) 0.92
Tobacco smoking in individuals with attention-deficit hyperactivity disorder: epidemiology and pharmacological approaches to cessation. CNS Drugs (2009) 0.91
Neurophysiology of Nicotine Addiction. J Addict Res Ther (2011) 0.91
Is a combination of varenicline and nicotine patch more effective in helping smokers quit than varenicline alone? A randomised controlled trial. BMC Med (2013) 0.90
Varenicline's effects on acute smoking behavior and reward and their association with subsequent abstinence. Psychopharmacology (Berl) (2010) 0.89
Varenicline dose dependently enhances responding for nonpharmacological reinforcers and attenuates the reinforcement-enhancing effects of nicotine. Nicotine Tob Res (2011) 0.88
Development of novel pharmacotherapeutics for tobacco dependence: progress and future directions. Nicotine Tob Res (2012) 0.88
Combination pharmacotherapy for stopping smoking: what advantages does it offer? Drugs (2010) 0.87
Preclinical Pharmacology, Efficacy and Safety of Varenicline in Smoking Cessation and Clinical Utility in High Risk Patients. Drug Healthc Patient Saf (2010) 0.86
A Review of Varenicline's Efficacy and Tolerability in Smoking Cessation Studies in Subjects with Schizophrenia. J Addict Res Ther (2011) 0.86
Naltrexone attenuation of conditioned but not primary reinforcement of nicotine in rats. Psychopharmacology (Berl) (2008) 0.85
Positive allosteric modulation of α4β2 nicotinic acetylcholine receptors as a new approach to smoking reduction: evidence from a rat model of nicotine self-administration. Psychopharmacology (Berl) (2013) 0.85
Varenicline for smoking cessation: efficacy, safety, and treatment recommendations. Patient Prefer Adherence (2010) 0.84
A double-blind placebo-controlled randomized trial of varenicline for smokeless tobacco dependence in India. Nicotine Tob Res (2013) 0.84
A novel recruitment message to increase enrollment into a smoking cessation treatment program: preliminary results from a randomized trial. Health Commun (2011) 0.83
Varenicline versus bupropion XL for smoking cessation in older adolescents: a randomized, double-blind pilot trial. Nicotine Tob Res (2011) 0.83
Biomarkers to optimize the treatment of nicotine dependence. Biomark Med (2011) 0.83
Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers. Neuropsychopharmacology (2015) 0.82
Differentiating the primary reinforcing and reinforcement-enhancing effects of varenicline. Psychopharmacology (Berl) (2014) 0.81
Mouse model predicts effects of smoking and varenicline on event-related potentials in humans. Nicotine Tob Res (2010) 0.81
Varenicline for tobacco dependence: panacea or plight? Expert Opin Pharmacother (2011) 0.81
Nicotine and Nicotine Abstinence Do Not Interfere with GABAA Receptor Neuroadaptations During Alcohol Abstinence. Alcohol Clin Exp Res (2016) 0.81
Unannounced telephone pill counts for assessing varenicline adherence in a pilot clinical trial. Patient Prefer Adherence (2011) 0.81
Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration. Prog Neuropsychopharmacol Biol Psychiatry (2010) 0.80
Psychological morbidity as a moderator of intention to quit smoking: a study of smokers and former smokers. J Bras Pneumol (2013) 0.80
Varenicline for smoking cessation: A review of the literature. Curr Ther Res Clin Exp (2009) 0.80
Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. Multidiscip Respir Med (2014) 0.79
Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking. BMC Public Health (2011) 0.79
Attentional bias retraining in cigarette smokers attempting smoking cessation (ARTS): study protocol for a double blind randomised controlled trial. BMC Public Health (2013) 0.79
Effects of the combination of metyrapone and oxazepam on intravenous nicotine self-administration in rats. Psychopharmacology (Berl) (2012) 0.78
Extended interactive voice response telephony (IVR) for relapse prevention after smoking cessation using varenicline and IVR: a pilot study. BMC Public Health (2013) 0.78
A systematic review of possible serious adverse health effects of nicotine replacement therapy. Arch Toxicol (2016) 0.77
Current and emerging pharmacotherapeutic options for smoking cessation. Subst Abuse (2013) 0.77
An exploratory short-term double-blind randomized trial of varenicline versus nicotine patch for smoking cessation in women. Addiction (2015) 0.77
Real world study to evaluate the effectiveness of varenicline and cognitive-behavioural interventions for smoking cessation. Int J Environ Res Public Health (2009) 0.77
HIV and smoking: associated risks and prevention strategies. HIV AIDS (Auckl) (2015) 0.77
Smoking cessation after brain damage does not lead to increased depression: implications for understanding the psychiatric complications of varenicline. Cogn Behav Neurol (2012) 0.76
The use of varenicline to treat nicotine dependence among patients with cancer. Psychooncology (2016) 0.76
A Comparison of the Fagerström Test for Cigarette Dependence and Cigarette Dependence Scale in a Treatment-Seeking Sample of Pregnant Smokers. Nicotine Tob Res (2015) 0.76
Update in new medications for primary care. J Gen Intern Med (2008) 0.75
Evaluation of the cardiovascular effects of varenicline in rats. Drug Des Devel Ther (2015) 0.75
The place of varenicline in smoking cessation treatment. Thorax (2008) 0.75
Smoking cessation: an economic analysis and review of varenicline. Clinicoecon Outcomes Res (2009) 0.75
Flexible, dual-form nicotine replacement therapy or varenicline in comparison with nicotine patch for smoking cessation: a randomized controlled trial. BMC Med (2016) 0.75
Attenuated nicotine-like effects of varenicline but not other nicotinic ACh receptor agonists in monkeys receiving nicotine daily. Br J Pharmacol (2016) 0.75
Cost-effectiveness of retreatment with varenicline after failure with or relapse after initial treatment for smoking cessation. Prev Med Rep (2015) 0.75
Clinically significant outcomes in smoking cessation. Thorax (2008) 0.75
Seven-day continuous abstinence rate from smoking at 1, 2, or 3 years after the use of varenicline. Tuberc Respir Dis (Seoul) (2015) 0.75
Pre-cessation varenicline treatment vs post-cessation NRT: an uneven playing field. Thorax (2008) 0.75
Cost-Effectiveness Analysis of Smoking Cessation Interventions in Japan Using a Discrete-Event Simulation. Appl Health Econ Health Policy (2016) 0.75
Effects of aging on the effectiveness of smoking cessation medication. Oncotarget (2016) 0.75
Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. Int J Chron Obstruct Pulmon Dis (2009) 0.75
ADHD symptoms impact smoking outcomes and withdrawal in response to Varenicline treatment for smoking cessation. Drug Alcohol Depend (2017) 0.75
Epistaxis and other haemorrhagic events associated with the smoking cessation medicine varenicline: a case series from two national pharmacovigilance centres. Eur J Clin Pharmacol (2012) 0.75
Effects of menthol and its interaction with nicotine-conditioned cue on nicotine-seeking behavior in rats. Psychopharmacology (Berl) (2017) 0.75
Identification and Characteristics of Time-Related Shifts in Suicide-Related Event Frequency During Smoking Cessation Treatment with Varenicline. Int J Med Sci (2017) 0.75
Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry (1986) 10.11
Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction (2004) 9.12
Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev (2004) 7.89
Cigarette smoking among adults--United States, 2000. MMWR Morb Mortal Wkly Rep (2002) 7.32
Outcome criteria in smoking cessation trials: proposal for a common standard. Addiction (2005) 6.36
Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA (2007) 6.09
Antidepressants for smoking cessation. Cochrane Database Syst Rev (2007) 4.62
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) 3.93
A double-blind study evaluating the long-term safety of varenicline for smoking cessation. Curr Med Res Opin (2007) 2.75
Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness. Addiction (2007) 2.38
Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev (2007) 2.27
A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther (2007) 2.06
Effectiveness of smoking cessation therapies: a systematic review and meta-analysis. BMC Public Health (2006) 1.91
Use of FDA-approved pharmacologic treatments for tobacco dependence--United States, 1984-1998. MMWR Morb Mortal Wkly Rep (2000) 1.91
Smoking cessation in patients with respiratory diseases: a high priority, integral component of therapy. Eur Respir J (2007) 1.78
Treating tobacco use and dependence: an introduction to the US Public Health Service Clinical Practice Guideline. Respir Care (2000) 1.75
Impact of UK policy initiatives on use of medicines to aid smoking cessation. Tob Control (2005) 1.63
Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis. Am J Health Behav (2008) 1.52
Nicotine-mecamylamine treatment for smoking cessation: the role of pre-cessation therapy. Exp Clin Psychopharmacol (1998) 1.38
Revealing the multidimensional framework of the Minnesota nicotine withdrawal scale. Curr Med Res Opin (2005) 1.26
Individual differences in smoking reward from de-nicotinized cigarettes. Nicotine Tob Res (2001) 1.21
A naturalistic cohort study on effectiveness, safety and usage pattern of an over-the-counter nicotine patch. Cohort study on smoking cessation. Eur J Clin Pharmacol (2003) 1.12
3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett (2005) 1.06
Stopping smoking can cause constipation. Addiction (2003) 1.05
Cystic fibrosis: current survival and population estimates to the year 2000. Thorax (1991) 7.12
Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet (1988) 4.85
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res (1993) 4.11
Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology (2006) 3.93
Validity and repeatability of the IUATLD (1984) Bronchial Symptoms Questionnaire: an international comparison. Eur Respir J (1989) 3.12
Descriptive epidemiology of bronchial reactivity in an adult population: results from a community study. Thorax (1987) 3.06
Asthma. Lancet (2002) 2.91
T-cell cytokine responses in human infection with Mycobacterium tuberculosis. Infect Immun (1995) 2.57
The p53/p63/p73 family of transcription factors: overlapping and distinct functions. J Cell Sci (2000) 2.55
Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet (1990) 2.52
T cell cytokine responses in persons with tuberculosis and human immunodeficiency virus infection. J Clin Invest (1994) 2.51
The effect of chemical treatments of albumin and orosomucoid on rate of clearance from the rat bloodstream and rate of pinocytic capture of rat yolk sac cultured in vitro. Biochem J (1977) 2.36
Phylogenetic analysis of rumen bacteria by comparative sequence analysis of cloned 16S rRNA genes. Anaerobe (1998) 2.31
Enhanced capacity of a widespread strain of Mycobacterium tuberculosis to grow in human macrophages. J Infect Dis (1999) 2.29
Interaction of glycogen synthase kinase 3beta with the DF3/MUC1 carcinoma-associated antigen and beta-catenin. Mol Cell Biol (1998) 2.29
Quantitative studies of pinocytosis. II. Kinetics of protein uptake and digestion by rat yolk sac cultured in vitro. J Cell Biol (1975) 2.20
Digestion of an exogenous protein by rat yolk-sac cultured in vitro. Biochem J (1971) 2.07
Assays of cell viability: discrimination of cells dying by apoptosis. Methods Cell Biol (1994) 2.06
What symptoms predict the bronchial response to histamine? Evaluation in a community survey of the bronchial symptoms questionnaire (1984) of the International Union Against Tuberculosis and Lung Disease. Int J Epidemiol (1989) 2.05
Response to inhaled histamine and 24 hour sodium excretion. Br Med J (Clin Res Ed) (1986) 2.01
Interleukin 12 at the site of disease in tuberculosis. J Clin Invest (1994) 1.98
The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents. Cancer Res (1993) 1.88
Quantitative studies of pinocytosis. I. Kinetics of uptake of (125I)polyvinylpyrrolidone by rat yolk sac cultured in vitro. J Cell Biol (1975) 1.86
Estimation and repeatability of the response to inhaled histamine in a community survey. Thorax (1987) 1.85
Management of asthma in schools. Arch Dis Child (1987) 1.81
Expression profiling suggested a regulatory role of liver-enriched transcription factors in human hepatocellular carcinoma. Cancer Res (2001) 1.78
Growth of virulent and avirulent Mycobacterium tuberculosis strains in human macrophages. Infect Immun (1998) 1.74
Comparison of bronchial reactivity and peak expiratory flow variability measurements for epidemiologic studies. Am Rev Respir Dis (1992) 1.73
Association between antioxidant vitamins and asthma outcome measures: systematic review and meta-analysis. Thorax (2009) 1.72
Permeability lesions in male Escherichia coli infected with bacteriophage T7. Proc Natl Acad Sci U S A (1975) 1.71
Clinical correlates of interferon gamma production in patients with tuberculosis. Clin Infect Dis (1997) 1.70
The distribution of peak expiratory flow variability in a population sample. Am Rev Respir Dis (1989) 1.66
A quantitative study of pinocytosis and intracellular proteolysis in rat peritoneal macrophages. Biochem J (1977) 1.64
Arctigenin, a natural compound, activates AMP-activated protein kinase via inhibition of mitochondria complex I and ameliorates metabolic disorders in ob/ob mice. Diabetologia (2011) 1.63
Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J Gastroenterol (2001) 1.62
Comparison of PD20 with two alternative measures of response to histamine challenge in epidemiological studies. Eur Respir J (1993) 1.61
Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence. Br J Pharmacol (2010) 1.59
Respiratory symptoms in patients with treated hypothyroidism and inflammatory bowel disease. Thorax (2003) 1.51
Absence of a prominent Th2 cytokine response in human tuberculosis. Infect Immun (1996) 1.51
Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia (1993) 1.50
Smoking cessation: a consensus statement with special reference to primary care. Int J Clin Pract (2001) 1.48
The role of white cells in the transmission of Yersinia enterocolitica in blood components. Transfusion (1992) 1.48
Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology (1999) 1.45
Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry (1994) 1.45
The pinocytosis of 125I-labelled poly(vinylpyrrolidone), [14C]sucrose and colloidal [198Au]gold by rat yolk sac cultured in vitro. Biochem J (1977) 1.43
Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene (2007) 1.40
Host Status of Different Bermudagrasses (Cynodon spp.) for the Sting Nematode, Belonolaimus longicaudatus. J Nematol (1992) 1.40
Inter-observer variation in the histopathological reporting of Hodgkin's disease: an analysis of diagnostic subcomponents using kappa statistics. Histopathology (1983) 1.40
Cytometry of cyclin proteins. Cytometry (1996) 1.40
Effects of weak bases on the degradation of endogenous and exogenous proteins by rat yolk sacs. Biochem J (1980) 1.40
Use of extinction and reinforcement to increase food consumption and reduce expulsion. J Appl Behav Anal (1997) 1.39
Membrane microparticles mediate transfer of P-glycoprotein to drug sensitive cancer cells. Leukemia (2009) 1.37
Regulation of ubiquitin-conjugating enzymes by glutathione following oxidative stress. J Biol Chem (1997) 1.36
Activation of the Saccharomyces cerevisiae filamentation/invasion pathway by osmotic stress in high-osmolarity glycogen pathway mutants. Genetics (1999) 1.33
Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy (2009) 1.32
Synergistic effect between EGF and TGF-beta1 in inducing oncogenic properties of intestinal epithelial cells. Oncogene (2007) 1.30
Single-cell cytokine analysis of gamma delta T cell responses to nonpeptide mycobacterial antigens. J Immunol (1997) 1.30
High-dose inhaled albuterol in severe chronic airflow limitation. Am Rev Respir Dis (1988) 1.30
CD30 in normal and neoplastic cells. Clin Immunol (1999) 1.29
Production of monocyte chemoattractant protein 1 in tuberculosis patients. Infect Immun (1998) 1.29
Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine (1999) 1.27
Silver-resistant mutants of Escherichia coli display active efflux of Ag+ and are deficient in porins. J Bacteriol (1997) 1.26
Bacterial meningitis in Navojo Indians. Public Health Rep (1976) 1.23
Prevalence of dementia and depression among elderly people in black and ethnic minorities. Br J Psychiatry (1997) 1.22
A quantitative study of pinocytosis and lysosome function in experimentally induced lysosomal storage. Biochem J (1976) 1.21
Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Hum Pathol (1996) 1.20
Antimicrobial activity of essential oils and structurally related synthetic food additives towards selected pathogenic and beneficial gut bacteria. J Appl Microbiol (2006) 1.19
IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcepsilonRI in human basophils. J Leukoc Biol (2001) 1.18
Hazard of smoking initiation by age among adolescents in Wuhan, China. Prev Med (2001) 1.15
DNA strand breaks occurring during apoptosis - their early insitu detection by the terminal deoxynucleotidyl transferase and nick translation assays and prevention by serine protease inhibitors. Int J Oncol (1992) 1.15
Mitochondrial genotype associated with longevity and its inhibitory effect on mutagenesis. Mech Ageing Dev (2000) 1.14
Rapid and sensitive detection of Singapore grouper iridovirus by loop-mediated isothermal amplification. J Appl Microbiol (2008) 1.13
Preparation and properties of liposome-associated gentamicin. Antimicrob Agents Chemother (1980) 1.13
Structure, function and regulation of p63 and p73. Cell Death Differ (1999) 1.12
Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl) (2001) 1.11
Effects of spectral smearing on phoneme and word recognition. J Acoust Soc Am (1996) 1.10
Liver disease in neonatal lupus erythematosus. J Pediatr (1990) 1.10
Group-specific 16S rRNA hybridization probes for determinative and community structure studies of Butyrivibrio fibrisolvens in the rumen. Appl Environ Microbiol (1997) 1.07
Use of texture fading in the treatment of food selectivity. J Appl Behav Anal (1998) 1.06
Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells. Cancer Res (1999) 1.06
5-Aminolevulinate synthase and the first step of heme biosynthesis. J Bioenerg Biomembr (1995) 1.06
16S rDNA analysis of Butyrivibrio fibrisolvens: phylogenetic position and relation to butyrate-producing anaerobic bacteria from the rumen of white-tailed deer. Lett Appl Microbiol (1996) 1.05
Comparison of histamine and methacholine for use in bronchial challenge tests in community studies. Thorax (1988) 1.05
Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study. Int J Clin Pract (2009) 1.05
Depressed CD40 ligand expression contributes to reduced gamma interferon production in human tuberculosis. Infect Immun (2000) 1.04
Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J Immunol (2000) 1.04
Geographical and social class effects on asthma mortality in England and Wales. Respir Med (1995) 1.04
Control of type II transforming growth factor-beta receptor expression by integrin ligation. J Biol Chem (1999) 1.04
LITAF and TNFSF15, two downstream targets of AMPK, exert inhibitory effects on tumor growth. Oncogene (2011) 1.03
The use of pharmacotherapies for smoking cessation during pregnancy. Tob Control (2000) 1.03
Neuropeptide Y: some viewpoints on a multifaceted peptide in the normal and diseased nervous system. Brain Res Brain Res Rev (1998) 1.02
Half-strength citrate CPD combined with a new additive solution for improved storage of red blood cells suitable for clinical use. Vox Sang (1993) 1.02
White cells protect donor blood against bacterial contamination. Transfusion (1991) 1.01
Relation of pulmonary lymphangio-leiomyomatosis to use of the oral contraceptive pill and fertility in the UK: a national case control study. Thorax (1994) 1.01
Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med (1996) 1.01
Specific thromboxane synthetase inhibition and albumin excretion rate in insulin-dependent diabetes. Lancet (1984) 1.00
Personal Social Capital Scale: an instrument for health and behavioral research. Health Educ Res (2008) 1.00
Synovial accumulation of technetium labelled liposomes in rheumatoid arthritis. Ann Rheum Dis (1987) 0.98